Claims

1. The compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula (Ia):



(Ia)

wherein Q^1 represents a hydrogen atom, a halogen atom, or $-OR^{10}$;

R^{10} represents a hydrogen atom, or (C_{1-6} alkyl)carbonyl optionally substituted with one or more halogen atoms;

R^2 represents $-COR^6$;

R^3 represents phenyl optionally substituted with one or more substituents selected from X^1, or 5- or 6-membered heteroaryl optionally substituted with one or more substituents selected from X^1;

R^4 represents a hydrogen atom, a halogen atom, $-OR^7$, or $-SR^8$;

R^5 represents a hydrogen atom or C_{1-6} alkyl;

R^6 represents C_{1-6} alkyl or C_{3-6} cycloalkyl;

R^7 represents a hydrogen atom, C_{1-6} alkyl, C_{1-6} alkoxyC_{1-6} alkyl, or (C_{1-6} alkyl)carbonyl optionally substituted with one or more halogen atoms;

R^8 represents C_{1-6} alkyl, or phenyl optionally substituted with one or more substituents selected from X^1; and

each X^1 is independently selected from C_{1-6} alkyl, a halogen atom, C_{1-6} alkoxy, nitro, and cyano.

2. The compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to Claim 1, whierein the compound is represented by Formula (Ic):



(Ic)

wherein R^6 is selected from C_{1-6} alkyl and C_{3-6} cycloalkyl;

R^3 represents phenyl optionally substituted with one or two halogen atoms, or 5- or 6-membered heteroaryl optionally substituted with one or two halogen atoms.

3. The compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to Claim 1 or 2, wherein the compound is selected from:

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)acetamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)propionamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)butylamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)hexanamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)cyclopropanecarboxamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)isobutylamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-

yl)(phenyl)methyl)pivalamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)cyclobutanecarboxamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)cyclopentanecarboxamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)-2,2-dimethylbutanamide; and

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)-3-methylbutanamide.

4. A pharmaceutical composition comprising the compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 3.

5. The pharmaceutical composition according to Claim 4, for use in treating or preventing a cognitive disease or disorder.

6. The pharmaceutical composition according to Claim 5, wherein the cognitive disease or disorder is selected from Alzheimer’s dementia, cerebrovascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson’s disease, a mental disease and a neurodegenerative disease.

7. The pharmaceutical composition according to Claim 4, for use in treating or preventing diabetes or a diabetic complication.

8. A Kir6.2 channel inhibitor comprising the compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to any one

of Claims 1 to 3.

9. A Kir6.1 channel inhibitor comprising the compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to any one of Claims 1 to 3.